Last reviewed · How we verify
CYT-0851 in combination with gemcitabine — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
CYT-0851 in combination with gemcitabine (CYT-0851 in combination with gemcitabine) — Cyteir Therapeutics, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| CYT-0851 in combination with gemcitabine TARGET | CYT-0851 in combination with gemcitabine | Cyteir Therapeutics, Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- CYT-0851 in combination with gemcitabine CI watch — RSS
- CYT-0851 in combination with gemcitabine CI watch — Atom
- CYT-0851 in combination with gemcitabine CI watch — JSON
- CYT-0851 in combination with gemcitabine alone — RSS
Cite this brief
Drug Landscape (2026). CYT-0851 in combination with gemcitabine — Competitive Intelligence Brief. https://druglandscape.com/ci/cyt-0851-in-combination-with-gemcitabine. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab